Food & Function,
Год журнала:
2023,
Номер
14(18), С. 8309 - 8320
Опубликована: Янв. 1, 2023
Astaxanthin
is
a
naturally
occurring
compound
that
possesses
immunomodulatory
properties.
The
results
of
our
previous
investigation
indicated
astaxanthin
has
the
potential
to
augment
anticancer
effectiveness
targeted
medication
sorafenib.
However,
precise
molecular
mechanism
underlying
this
phenomenon
remains
unclear.
H22
tumor-bearing
mice
were
treated
with
sorafenib
at
30
mg
kg-1
per
day
and
their
diet
was
supplemented
60
day-1
orally
for
period
18
days.
study
revealed
addition
facilitated
transition
tumor-associated
macrophages
from
M2
phenotype
M1
phenotype.
application
resulted
in
an
augmentation
CD8+
T
cell
infiltration
within
tumor
microenvironment
through
activation
CXCL9/CXCR3
signaling
axis.
found
enhance
production
cytokines
possess
antitumor
properties,
including
Granzyme
B.
Furthermore,
administration
alterations
intestinal
microbiota
H22-bearing
mice,
leading
growth
bacteria
anti-tumor
immune
such
as
Akkermansia.
findings
these
studies
indicate
response
against
tumors
when
used
conjunction
These
offer
novel
framework
advancement
agent
dietary
supplement
individuals
tumors.
Cancers,
Год журнала:
2023,
Номер
15(13), С. 3508 - 3508
Опубликована: Июль 5, 2023
The
burden
of
hepatocellular
carcinoma
(HCC)
continues
to
pose
a
significant
global
health
problem.
Several
systemic
therapies
have
recently
been
shown
improve
survival
for
patients
with
unresectable
disease.
However,
evidence
support
the
use
neoadjuvant
or
adjuvant
in
resectable
disease
is
limited,
despite
high
risk
recurrence.
Neoadjuvant
and
are
being
investigated
their
potential
reduce
recurrence
after
resection
overall
survival.
Our
review
identified
various
early-phase
clinical
trials
showing
impressive
preliminary
signals
pathologic
complete
response
disease,
others
suggesting
that
therapies-particularly
when
combined
strategies-may
convert
cause
tumor
necrosis,
potentially
decreasing
rates.
role
alone
may
also
play
part
management
these
patients,
particularly
reducing
Heterogeneity
trial
design,
used,
patient
selection,
scarcity
randomized
phase
III
necessitate
cautious
implementation
treatment
strategies.
Future
research
required
identify
predictive
biomarkers,
optimize
timing
type
therapeutic
combinations,
minimize
treatment-related
adverse
effects,
thereby
personalizing
enhancing
strategies
borderline
HCC.
Immune-oncology–based
regimens
have
shown
efficacy
in
advanced
HCC
and
been
implemented
as
standard
of
care
first-line
therapy.
Their
efficacy,
including
high
response
rates,
safety
justify
their
evaluation
earlier
disease
stages.
Following
negative
results
for
adjuvant
sorafenib
the
global
STORM
trial
2015,
4
phase
3
trials,
featuring
different
immune
checkpoint
inhibitor
combinations,
entered
parallel
race
setting.
The
IMbrave050
trial,
comparing
atezolizumab
combination
with
bevacizumab
to
active
surveillance
following
curative-intent
resection
or
ablation,
was
first
report,
fast-tracking
interim
analysis
demonstrating
an
improvement
recurrence-free
survival.
has
provoked
a
discussion
on
horizon
expectations
from
treatment
clinical
relevance
endpoints.
Moreover,
major
pathological
responses
reported
early
2
data
neoadjuvant
setting
provide
strong
rationale
these
concepts
trials.
In
this
review,
we
summarize
current
evidence
outline
future
directions
systemic
therapies
early-stage
HCC.
Journal of Hepatocellular Carcinoma,
Год журнала:
2023,
Номер
Volume 10, С. 181 - 191
Опубликована: Фев. 1, 2023
Abstract:
Hepatocellular
carcinoma
(HCC)
is
a
malignancy
that
requires
multidisciplinary
evaluation
to
develop
individualized
and
tailored
treatment
concepts.
While
liver
resection
transplantation
represent
the
mainstay
of
curative
in
patients
with
early-stage
HCC,
disease
recurrence
remains
an
important
burden.
Immune
checkpoint
inhibitors
(ICI)
have
become
standard
care
palliative
setting,
achieving
promising
response
rates
overall
good
tolerability.
Accordingly,
ICIs
are
being
evaluated
(neo)adjuvant
concepts
order
improve
survival.
Nevertheless,
neoadjuvant
therapies
not
recommended
by
current
guidelines
as
they
been
proven
outcome
large
Phase
III
trials
yet.
Especially
context
(LT),
perioperative
ICI
usage
need
particularly
critical
risk–benefit
assessment,
immunotherapy
may
significantly
increase
risk
rejection.
In
this
review,
we
summarize
available
data
on
ICI-based
strategies
HCC.
We
discuss
drawbacks
challenges
concept
specifically
highlight
allograft
rejection
when
given
(subsequently)
considered
for
transplantation.
Keywords:
hepatocellular
carcinoma,
immune
oncology,
inhibitor,
Food & Function,
Год журнала:
2023,
Номер
14(18), С. 8309 - 8320
Опубликована: Янв. 1, 2023
Astaxanthin
is
a
naturally
occurring
compound
that
possesses
immunomodulatory
properties.
The
results
of
our
previous
investigation
indicated
astaxanthin
has
the
potential
to
augment
anticancer
effectiveness
targeted
medication
sorafenib.
However,
precise
molecular
mechanism
underlying
this
phenomenon
remains
unclear.
H22
tumor-bearing
mice
were
treated
with
sorafenib
at
30
mg
kg-1
per
day
and
their
diet
was
supplemented
60
day-1
orally
for
period
18
days.
study
revealed
addition
facilitated
transition
tumor-associated
macrophages
from
M2
phenotype
M1
phenotype.
application
resulted
in
an
augmentation
CD8+
T
cell
infiltration
within
tumor
microenvironment
through
activation
CXCL9/CXCR3
signaling
axis.
found
enhance
production
cytokines
possess
antitumor
properties,
including
Granzyme
B.
Furthermore,
administration
alterations
intestinal
microbiota
H22-bearing
mice,
leading
growth
bacteria
anti-tumor
immune
such
as
Akkermansia.
findings
these
studies
indicate
response
against
tumors
when
used
conjunction
These
offer
novel
framework
advancement
agent
dietary
supplement
individuals
tumors.
